CNBC today published an article wherein the founder of Vanguard Group discussed his view on the necessity of investing in equities, which while higher risk, offer the potential for higher reward.
/apple-app-store.png?width=97&name=apple-app-store.png)
/google-play.png?width=88&name=google-play.png)
Posted by Laura Swartz
August 6, 2012 at 5:04 PM
CNBC today published an article wherein the founder of Vanguard Group discussed his view on the necessity of investing in equities, which while higher risk, offer the potential for higher reward.
Topics: Crystal Research Associates, T3 Motion, Advaxis, Bioniche, Pluristem Therapeutics, Peregrine, Adamis
As we kick off the New Year, many companies within our Coverage Universe are showing a positive start to 2011. For example, Canadian biopharmaceutical company Bioniche Life Sciences Inc. (BNC-TSX) recently raised A$12.5 million in Australia. Biotechnology company Xoma Ltd. (XOMA-NASDAQ) signed a development and licensing agreement potentially valued up to $505 million for an anti-inflammatory drug candidate. In addition, Advanced Cell Technology, Inc. ([“ACT”] ACTC-OTC.BB), a regenerative medicine company, announced that the FDA has cleared its Investigational New Drug application (IND) to test a therapy made from embryonic stem cells in patients with macular degeneration, a leading cause of vision loss. Further, the Tel-Aviv Stock Exchange (TASE) approved the inclusion of Pluristem Therapeutics Inc.’s (PSTI-NASDAQ) ordinary shares on four TASE equity indexes: Tel-Tech, TA Composite, MidCap TA, and Biomed.
Topics: Newsworthy Events, Bioniche, Pluristem Therapeutics, CEL-SCI
We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.
CONTACT INFORMATION
Phone: (212) 851-6685
/facebook.png)
FACEBOOK/twitter.png)
TWITTER/youtube.png)
YOUTUBE/linkedin.png)
LINKEDIN/slideshare.png)
SLIDESHARE/rss.png)
RSS